摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

sulfonic acid

中文名称
——
中文别名
——
英文名称
sulfonic acid
英文别名
sulphonic acid;acetoacetamide-N-sulfonic acid;hydroxy(dioxo)-λ6-sulfane
sulfonic acid化学式
CAS
——
化学式
H2O3S
mdl
——
分子量
82.0801
InChiKey
BDHFUVZGWQCTTF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.93
  • 重原子数:
    4.0
  • 可旋转键数:
    0.0
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    54.37
  • 氢给体数:
    2.0
  • 氢受体数:
    2.0

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Water soluble laser dyes
    摘要:
    提供了公式I的新型水溶性染料,其中R.sup.1和R.sup.4是1至4个碳原子的烷基或氢;或者R.sup.1-R.sup.2或R.sup.2-R.sup.4构成脂肪杂环环;R.sup.2是氢或与R.sup.1或R.sup.4结合,如上所述;R.sup.3是--(CH.sub.2).sub.m--SO.sub.3.sup.-,其中m为1至6;X为N、CH或##STR2##其中Y为2--SO.sub.3.sup.-;Z为3、4、5或6--SO.sub.3.sup.-。这些新型染料特别适用于水溶液染料激光器中的活性介质。
    公开号:
    US05792389A1
  • 作为产物:
    描述:
    乙酸乙酯 在 selenium(IV) oxide 、 氯化钠溶剂黄146三乙胺 作用下, 以35 %的产率得到sulfonic acid
    参考文献:
    名称:
    CYCLOTHEONELLAZOLEA, AND SYNTHETIC METHOD THEREFOR, AND APPLICATION METHOD THEREOF
    摘要:
    A CyclotheonellazoleA, a synthesis method therefor, and an application method thereof are provided, and a compound with a structure of formula (I) and a pharmaceutically acceptable salt thereof are provided, the structure of formula (I) is as follows: R 1 , R 2 , R 3 and R 4 are independently selected form the group consisting of a hydrogen group (H), an alkyl group with carbon atoms in a range of 1-6, an alkoxy group with carbon atoms in a range of 1-6, a halogen group, a hydroxyl group, an amino group, a nitro group, a cyano group and a sulfydryl group. A CyclotheonellazoleA natural product is successfully synthesized by a classical retrosynthesis analysis, a stereoscopic structure of the CyclotheonellazoleA natural product is confirmed, extremely excellent protease inhibitory activity of the CyclotheonellazoleA natural product is confirmed by combining a protease inhibition activity experiment, and the CyclotheonellazoleA has a strong application prospect in a pharmaceutical industry.
    公开号:
    US20240254162A1
  • 作为试剂:
    描述:
    3,3,4,5,5-pentafluoro-2-prop-2-enylpent-4-enoic acid 、 异丁烯sulfonic acid 作用下, 以 二氯甲烷 为溶剂, 反应 5.5h, 生成 3,3,4,5,5-Pentafluoro-2-allyl-4-pentenoic acid tert-butyl ester
    参考文献:
    名称:
    Fluorinated compound, fluoropolymer and method for producing the compound
    摘要:
    提供一种新型氟化合物、氟聚合物以及制备该化合物的方法。 一种由下式表示的化合物CF2═CFCF2C(X)(C(O)OZ)(CH2)nCR═CHR(其中X为氢原子、氰基或由式—C(O)OZ表示的基团,Z为氢原子或C1-20单价有机基团,n为0、1或2,R为氢原子或C1-20单价有机基团),以及制备该化合物的方法,以及通过聚合该化合物获得的氟聚合物。
    公开号:
    US07825275B2
点击查看最新优质反应信息

文献信息

  • Aminoazole derivatives and their production and use
    申请人:Sumitomo Pharmaceuticals Company, Limited
    公开号:US04914112A1
    公开(公告)日:1990-04-03
    A compound of the formula: ##STR1## wherein A is the group of the formula: Ar.sup.1 --D--Ar.sup.2 -- wherein Ar.sup.1 is a phenyl or thienyl group which may be optionally substituted with at least one of the same or different halogen atom; Ar.sup.2 is a phenylene or thienylene group which may be optionally substituted with at least one of the same or different halogen atom; D is a divalent radical selected from the group consisting of >C.dbd.N--OR.sup.4 [wherein R.sup.4 is a hydrogen atom or lower alkyl group], >C.dbd.O, ##STR2## >CHOH, >NH radical, or single bond, ##STR3## wherein R.sup.5 is a lower alkoxy or a phenyl group which may be optionally substituted with at least one of the same or different halogen atom; E is a methine group or a nitrogen atom; F is a vinylene group or an oxygen atom, ##STR4## wherein R.sup.6 is a lower alkoxy group; R.sup.7 is a lower alkyl group; R.sup.8 is a benzoyl group which may be optionally substituted with at least one of the same or different halogen atom, B is a divalent azole group; R.sup.1 is a hydrogen atom or a lower alkyl group; R.sup.2 is a hydrogen atom, lower alkyl, aryl-lower alkyl, or the group of the formula: R.sup.9 --G-- wherein R.sup.9 is a hydrogen atom, lower alkyl, halo-lower alkyl, amino-lower alkyl, aryl or aryl-lower alkyl group or the group of the formula: ##STR5## wherein R.sup.10 is a hydrogen atom or lower alkoxy group; R.sup.11 is a hydrogen atom, lower alkyl, lower alkenyl, lower cycloalkyl, aryl-lower alkyl, aryl or aroyl group; or the group of the formula: --NR.sup.10 R.sup.11 is a 5-, 6- or 7-membered saturated heterocyclic ring; or the group of the formula: R.sup.12 --O-- wherein R.sup.12 is a lower alkyl or polyhalo-lower alkyl group; G is a divalent group selected from the group consisting of >C.dbd.O, >C.dbd.S, >(C.dbd.O).sub.2 or >SO.sub.2 radical; or the group of the formula: --NR.sup.1 R.sup.2 is a 5-, 6- or 7-membered saturated heterocyclic ring: R.sup.3 is a hydrogen atom or lower alkyl group, or its acid addition salts, which is useful for immunomodulator.
    该化合物的化学式为:##STR1## 其中A是该式的基团:Ar.sup.1 --D--Ar.sup.2 -- 其中Ar.sup.1是苯基或噻吩基团,可以选择性地用相同或不同的卤原子取代;Ar.sup.2是苯基或噻吩基团,可以选择性地用相同或不同的卤原子取代;D是从以下组中选择的二价基团:>C.dbd.N--OR.sup.4 [其中R.sup.4是氢原子或较低的烷基基团],>C.dbd.O,##STR2## >CHOH,>NH基团,或单键,##STR3## 其中R.sup.5是较低的烷氧基或苯基团,可以选择性地用相同或不同的卤原子取代;E是亚甲基基团或氮原子;F是乙烯基团或氧原子,##STR4## 其中R.sup.6是较低的烷氧基;R.sup.7是较低的烷基基团;R.sup.8是苯甲酰基团,可以选择性地用相同或不同的卤原子取代,B是二价唑基团;R.sup.1是氢原子或较低的烷基基团;R.sup.2是氢原子,较低的烷基,芳基-较低的烷基,或该式的基团:R.sup.9 --G-- 其中R.sup.9是氢原子,较低的烷基,卤代较低的烷基,氨基-较低的烷基,芳基或芳基-较低的烷基团,或该式的基团:##STR5## 其中R.sup.10是氢原子或较低的烷氧基;R.sup.11是氢原子,较低的烷基,较低的烯基,较低的环烷基,芳基-较低的烷基,芳基或芳酰基团;或该式的基团:--NR.sup.10 R.sup.11是5、6或7-成员饱和杂环;或该式的基团:R.sup.12 --O-- 其中R.sup.12是较低的烷基或多卤代较低的烷基基团;G是从以下组中选择的二价基团:>C.dbd.O,>C.dbd.S,>(C.dbd.O).sub.2或>SO.sub.2基团;或该式的基团:--NR.sup.1 R.sup.2是5、6或7-成员饱和杂环:R.sup.3是氢原子或较低的烷基基团,或其酸盐,用于免疫调节剂。
  • N-(4-piperidinyl)-N-phenylamides and -carbamates
    申请人:Janssen Pharmaceutica N.V.
    公开号:US03998834A1
    公开(公告)日:1976-12-21
    Novel N-(4-piperidinyl)-N-phenylamides and -carbamates having very potent analgesic activity, methods of preparing same and useful intermediates therefor.
    新型具有非常强的镇痛活性的N-(4-哌啶基)-N-苯基酰胺和-氨基甲酸酯,其制备方法及有用的中间体。
  • Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
    申请人:Aventis Pharma Deutschland GmbH
    公开号:US06281227B1
    公开(公告)日:2001-08-28
    The compounds of formula I herein exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, for treating a patient suffering from, or subject to, a physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.
    本文中的化合物具有有用的药理活性,因此被纳入药物组合物中,并用于治疗患有某些医学疾病的患者。更具体地说,它们是凝血因子Xa活性的抑制剂。本发明涉及具有I式化合物的化合物、含有I式化合物的组合物,以及它们的用途,用于治疗患有或受到生理状况影响的患者,这些生理状况可以通过给予凝血因子Xa活性抑制剂来改善。
  • N-arylation of isatins
    申请人:Abbott Laboratories
    公开号:US05151518A1
    公开(公告)日:1992-09-29
    A process for the N-arylation of isatins with organo bismuth reagents is disclosed.
    揭示了一种使用有机铋试剂对异喹啉进行N-芳基化的方法。
  • Il-8 receptor anatagonists
    申请人:——
    公开号:US20030216375A1
    公开(公告)日:2003-11-20
    This invention relates to novel compounds of Formula (I), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
    该发明涉及式(I)的新化合物及其组合物,用于治疗由趋化因子白细胞介素-8(IL-8)介导的疾病状态。
查看更多